1285533-84-7

Basic information

• Product Name: Sorafenib Impurity 6
• Synonyms: Sorafenib Impurity 6;N-methyl-4-(4-(3-(3-(trifluoromethyl)phenyl)ureido)phenoxy)picolinamide
• CAS NO: 1285533-84-7
• Molecular Formula: C₂₁H₁₇F₃N₄O₃
• Molecular Weight: 430.39
• Mol File: 1285533-84-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 187.6 °C
• Boiling Point: 498.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.399±0.06 g/cm3(Predicted)
• PKA: 13.39±0.70(Predicted)
• CAS DataBase Reference: Sorafenib Impurity 6(CAS DataBase Reference)
• NIST Chemistry Reference: Sorafenib Impurity 6(1285533-84-7)
• EPA Substance Registry System: Sorafenib Impurity 6(1285533-84-7)

Safety Data

• Hazardous Substances Data: 1285533-84-7(Hazardous Substances Data)

Usage

Uses

N-Methyl-4-[4-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinecarboxamide is an impurity of Sorafenib (S676850); a multiple kinase inhibitor targeting both RAF and receptor tyrosine kinases that promote angiogenesis. Also antineoplastic.

Upstream product

• 5470-22-4 4-chloropicolinic acid 
• 220000-87-3 4-chloro-N-methylpicolinamide 
• 98-16-8 3-trifluoromethylaniline 
• 123-30-8 4-amino-phenol 
• 51727-15-2 4-chloro-2-pyridine carboxylic acid chloride hydrochloride 
• 284462-37-9 4-(4-aminophenoxy)-N-methylpyridine-2-carboxamide 
• 329-01-1 1-isocyanato-3-trifluoromethyl-benzene 
• 98-98-6 2-Picolinic acid 

Relevant articles and documents

Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity against VEGFR2, p38α, and B-Raf

A series of diarylurea inhibitors of the cardiac-specific kinase TNNI3K were developed to elucidate the biological function of TNNI3K and evaluate TNNI3K as a therapeutic target for the treatment of cardiovascular diseases. Utilizing a structure-based design, enhancements in kinase selectivity were engineered into the series, capitalizing on the established X-ray crystal structures of TNNI3K, VEGFR2, p38α, and B-Raf. Our efforts culminated in the discovery of an in vivo tool compound 47 (GSK329), which exhibited desirable TNNI3K potency and rat pharmacokinetic properties as well as promising kinase selectivity against VEGFR2 (40-fold), p38α (80-fold), and B-Raf (>200-fold). Compound 47 demonstrated positive cardioprotective outcomes in a mouse model of ischemia/reperfusion cardiac injury, indicating that optimized exemplars from this series, such as 47, are favorable leads for discovering novel medicines for cardiac diseases.

SORAFENIB ANALOGS AND USES THEREOF

The present invention provides, inter alia, compounds according to formula I. Also provided are pharmaceutical compositions and kits containing such compounds. Methods for using such compounds, compositions, and kits for treating a subject having system xc-, dysregulation for activating ferroptosis, for inhibiting system xc- in a cell, and for monitoring treatment of a subject having system xc- dysregulation are provided as well.